These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 12911348)

  • 1. Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.
    Vigor K; Emerson J; Scott R; Cheek J; Barton C; Bax HJ; Josephs DH; Karagiannis SN; Spicer JF; Lentfer H
    Biotechnol Prog; 2016 Nov; 32(6):1494-1502. PubMed ID: 27604040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Different Container Types on (1→3)-β-D-glucan Recovery.
    Burgmaier L; Illes B; Leiss M; Avci-Adali M; Reich J
    Molecules; 2023 Oct; 28(19):. PubMed ID: 37836774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a quantification method for β-glucans and their immune activity potential for quality control of β-glucan containing products.
    Schulze C; Stamer LLM; Huss SK; Schaufler K; Guenther S; Schultze N
    Carbohydr Res; 2021 Jun; 504():108327. PubMed ID: 33934035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Glucan fragmentation by microfluidization and TNF-α-immunostimulating activity of fragmented β-glucans.
    Nanta P; Buachan P; Pinket W; Srinuanchai W; Pongwan P; Sramala I; Jarussophon S; Prathumpai W; Taweechotipatr M; Ruktanonchai UR; Kasemwong K
    Heliyon; 2024 Apr; 10(8):e29444. PubMed ID: 38628769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multipronged approach to managing beta-glucan contaminants in the downstream process: control of raw materials and filtration with charge-modified nylon 6,6 membrane filters.
    Gefroh E; Hewig A; Vedantham G; McClure M; Krivosheyeva A; Lajmi A; Lu Y
    Biotechnol Prog; 2013; 29(3):672-80. PubMed ID: 23596143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal Blood Bacteriome, Gut Dysbiosis, and Progression to Severe Dengue Disease.
    Chancharoenthana W; Kamolratanakul S; Ariyanon W; Thanachartwet V; Phumratanaprapin W; Wilairatana P; Leelahavanichkul A
    Front Cell Infect Microbiol; 2022; 12():890817. PubMed ID: 35782108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil Extracellular Traps in Severe SARS-CoV-2 Infection: A Possible Impact of LPS and (1→3)-β-D-glucan in Blood from Gut Translocation.
    Saithong S; Worasilchai N; Saisorn W; Udompornpitak K; Bhunyakarnjanarat T; Chindamporn A; Tovichayathamrong P; Torvorapanit P; Chiewchengchol D; Chancharoenthana W; Leelahavanichkul A
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possibility of Japanese Cedar Pollen Causing False Positives in the Deep Mycosis Test.
    Kanno T; Kim C; Yamanaka D; Ishibashi KI; Tanaka H; Ohno N; Adachi Y
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease.
    Finkelman MA
    J Fungi (Basel); 2020 Dec; 7(1):. PubMed ID: 33383818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach.
    Moura S; Cerqueira L; Almeida A
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1393-1403. PubMed ID: 29754210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors.
    Hammarström H; Kondori N; Friman V; Wennerås C
    Eur J Clin Microbiol Infect Dis; 2015 May; 34(5):917-25. PubMed ID: 25573536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental proof of contamination of blood components by (1-->3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process.
    Nagasawa K; Yano T; Kitabayashi G; Morimoto H; Yamada Y; Ohata A; Usami M; Horiuchi T
    J Artif Organs; 2003; 6(1):49-54. PubMed ID: 14598125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing.
    Usami M; Ohata A; Horiuchi T; Nagasawa K; Wakabayashi T; Tanaka S
    Transfusion; 2002 Sep; 42(9):1189-95. PubMed ID: 12430677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship of (1-->3)-beta-D-glucans in the induction of cytokine production from macrophages, in vitro.
    Okazaki M; Adachi Y; Ohno N; Yadomae T
    Biol Pharm Bull; 1995 Oct; 18(10):1320-7. PubMed ID: 8593430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma (1-->3)-beta-D-glucan determination for screening deep mycosis].
    Obayashi T
    Rinsho Byori; 1996 Jun; 44(6):528-32. PubMed ID: 8752730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-glucan contamination of pharmaceutical products: How much should we accept?
    Barton C; Vigor K; Scott R; Jones P; Lentfer H; Bax HJ; Josephs DH; Karagiannis SN; Spicer JF
    Cancer Immunol Immunother; 2016 Nov; 65(11):1289-1301. PubMed ID: 27473075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of (1-->3)-beta-D-glucan from depth-type membrane filters and their in vitro effects on proinflammatory cytokine production.
    Ohata A; Usami M; Horiuchi T; Nagasawa K; Kinoshita K
    Artif Organs; 2003 Aug; 27(8):728-35. PubMed ID: 12911348
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.